324 related articles for article (PubMed ID: 28522750)
1. Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses.
Karpel-Massler G; Ishida CT; Bianchetti E; Shu C; Perez-Lorenzo R; Horst B; Banu M; Roth KA; Bruce JN; Canoll P; Altieri DC; Siegelin MD
Cancer Res; 2017 Jul; 77(13):3513-3526. PubMed ID: 28522750
[TBL] [Abstract][Full Text] [Related]
2. BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Ishida CT; Bianchetti E; Shu C; Halatsch ME; Westhoff MA; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 May; 8(18):29558-29573. PubMed ID: 28418907
[TBL] [Abstract][Full Text] [Related]
3. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial matrix chaperone and c-myc inhibition causes enhanced lethality in glioblastoma.
Ishida CT; Shu C; Halatsch ME; Westhoff MA; Altieri DC; Karpel-Massler G; Siegelin MD
Oncotarget; 2017 Jun; 8(23):37140-37153. PubMed ID: 28415755
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma.
Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557
[TBL] [Abstract][Full Text] [Related]
6. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.
Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387
[TBL] [Abstract][Full Text] [Related]
7. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
8. BH3 mimetics: status of the field and new developments.
Billard C
Mol Cancer Ther; 2013 Sep; 12(9):1691-700. PubMed ID: 23974697
[TBL] [Abstract][Full Text] [Related]
9. Development of Noxa-like BH3 mimetics for apoptosis-based therapeutic strategy in chronic lymphocytic leukemia.
Billard C
Mol Cancer Res; 2012 Jun; 10(6):673-6. PubMed ID: 22466256
[TBL] [Abstract][Full Text] [Related]
10. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
[TBL] [Abstract][Full Text] [Related]
11. BH3 mimetics inhibit growth of chondrosarcoma--a novel targeted-therapy for candidate models.
Morii T; Ohtsuka K; Ohnishi H; Mochizuki K; Yoshiyama A; Aoyagi T; Hornicek FJ; Ichimura S
Anticancer Res; 2014 Nov; 34(11):6423-30. PubMed ID: 25368242
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
13. Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo.
Karpel-Massler G; Ramani D; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD
Oncotarget; 2016 Jun; 7(23):33512-28. PubMed ID: 27172899
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HDAC1/2 Along with TRAP1 Causes Synthetic Lethality in Glioblastoma Model Systems.
Nguyen TTT; Zhang Y; Shang E; Shu C; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD
Cells; 2020 Jul; 9(7):. PubMed ID: 32664214
[TBL] [Abstract][Full Text] [Related]
15. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
[TBL] [Abstract][Full Text] [Related]
16. A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria.
Wang X; Zhang C; Yan X; Lan B; Wang J; Wei C; Cao X; Wang R; Yao J; Zhou T; Zhou M; Liu Q; Jiang B; Jiang P; Kesari S; Lin X; Guo F
Clin Cancer Res; 2016 Mar; 22(6):1445-58. PubMed ID: 26515494
[TBL] [Abstract][Full Text] [Related]
17. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition.
Bate-Eya LT; den Hartog IJ; van der Ploeg I; Schild L; Koster J; Santo EE; Westerhout EM; Versteeg R; Caron HN; Molenaar JJ; Dolman ME
Oncotarget; 2016 May; 7(19):27946-58. PubMed ID: 27056887
[TBL] [Abstract][Full Text] [Related]
18. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
19. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
[TBL] [Abstract][Full Text] [Related]
20. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis.
Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S
Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
